Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
Historique:
received: 15 10 2020
revised: 21 01 2021
accepted: 26 01 2021
pubmed: 2 2 2021
medline: 25 8 2021
entrez: 1 2 2021
Statut: ppublish

Résumé

The histone methyltransferase EZH2 has been the target of numerous small-molecule inhibitor discovery efforts over the last 10+ years. Emerging clinical data have provided early evidence for single agent activity with acceptable safety profiles for first-generation inhibitors. We have developed kinetic methodologies for studying EZH2-inhibitor-binding kinetics that have allowed us to identify a unique structural modification that results in significant increases in the drug-target residence times of all EZH2 inhibitor scaffolds we have studied. The unexpected residence time enhancement bestowed by this modification has enabled us to create a series of second-generation EZH2 inhibitors with sub-pM binding affinities. We provide both biophysical evidence validating this sub-pM potency and biological evidence demonstrating the utility and relevance of such high-affinity interactions with EZH2.

Identifiants

pubmed: 33524394
pii: S0021-9258(21)00121-6
doi: 10.1016/j.jbc.2021.100349
pmc: PMC7949150
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
Small Molecule Libraries 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100349

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Jacob I Stuckey (JI)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Nico R Cantone (NR)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Alexandre Côté (A)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Shilpi Arora (S)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Valerie Vivat (V)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Ashwin Ramakrishnan (A)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Jennifer A Mertz (JA)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Avinash Khanna (A)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Jehrod Brenneman (J)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Victor S Gehling (VS)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Ludivine Moine (L)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Robert J Sims (RJ)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

James E Audia (JE)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Patrick Trojer (P)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Julian R Levell (JR)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA.

Richard T Cummings (RT)

Constellation Pharmaceuticals, Cambridge, Massachusetts, USA. Electronic address: richard.cummings@constellationpharma.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH